Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07527819 2026-04-14

FERTILE

Not yet recruiting

75 enrolled

BreastGynecologic

Inflammation, Primary Ovarian Insufficiency, Triple Negative Breast Neoplasms

NCT04314401 2026-04-13

National Cancer Institute "Cancer Moonshot Biobank"

Active not recruiting

1,600 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

BELIEVE

FERTILE

National Cancer Institute "Cancer Moonshot Biobank"

Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

AIDOBE

PERCEPTION

TRIPLEX

MIMIR-mTNBC

FORTITUDE

MINA

GEMINI Breast

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

PDO-Mercurial

BASECAMP-1

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

Study of Screening Brain MRIs in Stage IV Breast Cancer

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

ELEPHAS-05

ENCORE

INSTIGO

PDO-Neo01

NEUTROFLOW

Axillary Nodal Burden in HER2+ and TNBC

PROGECT

BRAVA

Comparison of the Breast Tumor Microenvironment

PEAR-TNBC

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

DESCENT-1

Role of the Immune Environment in Response to Therapy in Breast Cancer

START

Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

TIL; PD1; PDL1

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

OPTImaL

A Multicenter Cancer Biospecimen Collection Study

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

B-STRONGER-I

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

NeoTNBCX

Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

NacTNBC

Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

A-TRAIN

Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity

Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer